High correlation for CLD workflows with simpler operation
Agenus UK evaluated the Amperia platform alongside BLI and SPR for antibody titre analysis during a cell line development campaign. The study demonstrated strong correlation between platforms and showed that Amperia could support reliable clone ranking with reduced setup time and streamlined operation. The team found it particularly well-suited for routine analysis in early-stage workflows.
Highlights:
- Compared with BLI and SPR across more than 80 samples
- Demonstrated consistent, reproducible results
- Supported clone selection in upstream development
- Reduced complexity in day-to-day titre analysis